Technology

We aim to continuously advance our ADC pipeline by leveraging our two core technology platforms, namely the PAD molecular design platform and the MabArray target discovery platform. Through this integrated platform ecosystem, we can rapidly identify novel tumor- specific targets, design optimized ADC constructs, and accelerate the progression of next-generation candidates from discovery to clinical evaluation.